Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics in pancreatic cancer.

JOP : Journal of the pancreas - 28 Jul 2014

Tourkantonis Ioannis S, Peponi Evangelia, Syrigos Konstantinos N, Saif Muhammad Wasif

Abstract excerpt

Pancreatic cancer is an aggressive malignancy with a poor overall survival rate. Given advances in pharmacogenomics, numerous gene mutations have been identified that could be potential targets for drug development. Therefore, future research strategies may identify prognostic and predictive markers aiming to improve outcome by maximizing efficacy whilst lowering toxicity. In this commentary, we summarize several...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Deoxycytidine

Share to Gemcitabine

Share to Glucuronosyltransferase

Share to Pancreatic Neoplasms

Share to Pharmacogenetics

Source

Identifiers

PMID: 25076337
DOI: 10.6092/1590-8577/2689

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics in pancreatic cancer.PMID 25076337Read ↗

Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.Semantic proximity Read ↗

Pharmacogenetics of anticancer drug sensitivity in pancreatic cancerSemantic proximity Read ↗

Clinical pharmacology and pharmacogenetics of gemcitabineSemantic proximity Read ↗

Pharmacogenomics of Gemcitabine in Non-Small-Cell Lung Cancer and Other Solid TumorsSemantic proximity Read ↗

Pharmacogenetics in neuroendocrine tumors of the pancreas.Semantic proximity Read ↗

Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer.Semantic proximity Read ↗

Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy.Semantic proximity Read ↗

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial.Semantic proximity Read ↗

Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy.Semantic proximity Read ↗

Genetic variations associated with gemcitabine treatment outcome in pancreatic cancerSemantic proximity Read ↗

Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.Semantic proximity Read ↗

Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.